

Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies Targeting the Non-Shed MUC16 Region

Leveraging iBio's Epitope Steering, ShieldTx, and EngageTx Technologies

MUC16 Potentially for Ovarian and Other Cancers



Target Mechanism

Bind a membraneproximal MUC16 epitope

Membrane-proximal binding avoids epitope elimination by tumors

Bind a non-glycosylated epitope to avoid altered glycosylation on tumors


強 Potential Indications

- Ovarian
- Uterine
- Pancreatic




Differentiation / Opportunity

- MUC16 epitope avoids primary modes of tumor evasion
- Enabling modalities: T Cell engager, ADC, CAR-T






MUC16 Is Overexpressed and Shed by Tumor Cells






Immunizations Were Steered to a MUC16 Epitope that Avoids Epitope Shedding






Top Three Hit Clones Bind the Non-Glycosylated MUC16 Epitope Closest to the Membrane

Hits do not bind shed 230-mer





Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Regeneron Benchmark






8G4 Clone Maintains OVCAR-3 Cell and MUC16 Epitope Binding in a Fully Human Framework

8G4 with fully human framework reduces immunogenicity risk


Cell binding



Glycosylated MUC16 membraneproximal epitope SPR:


KD = 5.1 nM


Epitope binding






Efficient Expression with 2x2 Format: Anti-CD3 x MUC16 Bispecific T-Cell Engagers








2X2 Anti-CD3 X MUC16 T Cell Engagers Stimulate T Cells in Donor PBMCs





2X2 Anti-CD3 X MUC16 T Cell Engagers Kill OVCAR-3 Ovarian Cancer Cells





CD3 Arms

ShieldTx Engineered Epitope Mask Conditionally Activates MUC16 and CD3 Hits

